Panavance Therapeutics Inc.
Michelle Hicks is currently working as a Quality Assurance / CMC at Panavance Therapeutics Inc. and as a Senior Quality Assurance Consultant at Geistlich Biomaterials - North America. With extensive experience in quality assurance and regulatory affairs, Michelle has held various positions such as Head of Quality Assurance at Vascular Strategies LLC, QA/RA and Clinical Consultant at BioArray Solutions, Ltd., and Project Manager at Lonza. Michelle has also worked as a Global Systems Administrator at Johnson & Johnson and as a Clinical Trials Consultant at Becton Dickinson. Michelle holds a Bachelor's Degree in Biology and Psychology from Indiana University Bloomington.
Panavance Therapeutics Inc.
Panavance Therapeutics Inc. is a US, clinical-stage pharmaceutical company established in 2021 by the Swiss-based Avensis Pharma AG, a subsidiary of Ed. Geistlich Söhne AG für Chemische Industrie. Panavance is focused on advancing the development of GP-2250, a novel oncology therapeutic intended to improve outcomes and quality of life for patients with cancer. With its highly capable team and strong academic and industry partnerships, Panavance is pursuing a rigorous program to bring GP-2250 to patients around the world.